Entropy Neurodynamics

Entropy Neurodynamics EPS Growth

The EPS Growth of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 18.51 %. In the previous year, EPS Growth was 33.91 % — a change of -45.42% (lower).

EPS Growth

18.51 %

YoY

-45.42%

Last updated:

EPS Growth of Entropy Neurodynamics is 2026 18.51 % . EPS Growth of Entropy Neurodynamics was 2025 33.91 % . It decreases by -45.42% lower compared to the previous year.

The Entropy Neurodynamics EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
-577.31 AUD
Jan 1, 2020
-84.47 AUD
Jan 1, 2021
-18.41 AUD
Jan 1, 2022
-19.05 AUD
Jan 1, 2023
71.40 AUD
Jan 1, 2024
86.75 AUD
Jan 1, 2025
33.91 AUD
Jan 1, 2026
18.51 AUD
The Entropy Neurodynamics EPS Growth history
YEAREPS GrowthYoY
18.51 %-45.42%
33.91 %-60.91%
86.75 %+21.49%
71.40 %-474.74%
-19.05 %+3.50%
-18.41 %-78.21%
-84.47 %-85.37%
-577.31 %-99.98%
-2.40 M %+1.85 M%
-129.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

EPS Growth of Entropy Neurodynamics is 18.51 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics